journal
MENU ▼
Read by QxMD icon Read
search

Biology of Blood and Marrow Transplantation

journal
https://www.readbyqxmd.com/read/29793046/validation-of-the-revised-pam-score-in-patients-with-aml-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#1
Jan M Middeke, Frederike Kollinger, Henning Baldauf, Friedrich Stölzel, Martin Wermke, Malte von Bonin, Katja Sockel, Cornelia S Link, Raphael Teipel, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
PURPOSE: Despite recent advances, allogeneic hematopoietic stem cell transplantation (alloHSCT) continues to be accompanied by a high rate of morbidity and mortality. Several scores have been developed to predict outcome after HSCT. The PAM score has been recently revised, and utilizes information on patient age, donor type, disease risk, cytomegalovirus (CMV) serostatus of patients and donors, and the forced expiratory volume in one second (FEV1). The aim of this study was to analyze the predictive power of the PAM score in an independent, large cohort of acute myeloid leukemia (AML) patients...
May 21, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29782992/single-ultra-high-dose-cholecalciferol-to-prevent-vitamin-d-deficiency-in-pediatric-hematopoietic-stem-cell-transplantation
#2
Gregory Wallace, Sonata Jodele, Kasiani C Myers, Christopher E Dandoy, Javier El-Bietar, Adam Nelson, Ashley Teusink-Cross, Pooja Khandelwal, Cynthia Taggart, Catherine M Gordon, Stella M Davies, Jonathan C Howell
BACKGROUND: Vitamin D (vitD) deficiency is prevalent among childhood hematopoietic stem cell transplantation (HSCT) recipients and associated with inferior transplant survival at 100 days after transplantation. Achieving and maintaining therapeutic vitD levels in HSCT recipients is extremely challenging in the first 3-6 months after transplant due to poor compliance in the setting of mucositis, and concomitant use of critical transplant drugs that interfere with vitD absorption. We sought to evaluate the safety and efficacy of a single, ultra-high dose of vitD given prior to childhood HSCT to maintain levels in a therapeutic range during the peri-transplantation period...
May 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29777868/comparative-efficacy-and-safety-of-different-antiviral-agents-for-cytomegalovirus-prophylaxis-in-allogeneic-hematopoietic-cell-transplantation-a-systematic-review-and-meta-analysis
#3
Nico Gagelmann, Per Ljungman, Jan Styczynski, Nicolaus Kröger
Over the past 25 years, several randomized controlled trials have investigated the efficacy of different antiviral agents for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic-cell transplantation. We performed a systematic literature review, conventional meta-analysis and network meta-analysis using a random-effects model and risk ratios (RR) with corresponding 95% confidence intervals (CI) as effect estimates. Fifteen randomized controlled trials were identified, including seven different antiviral agents: acyclovir, ganciclovir, maribavir, brincidofovir, letermovir, valacyclovir, and vaccine...
May 16, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29777867/antibiotic-exposure-prior-to-respiratory-viral-infection-is-associated-with-progression-to-lower-respiratory-tract-disease-in-allogeneic-hematopoietic-cell-transplant-recipients
#4
Chikara Ogimi, Elizabeth M Krantz, Jonathan L Golob, Alpana Waghmare, Catherine Liu, Wendy M Leisenring, Christopher R Woodard, Sara Marquis, Jane M Kuypers, Keith R Jerome, Steven A Pergam, David N Fredricks, Mohamed L Sorror, Janet A Englund, Michael Boeckh
INTRODUCTION: Recent publications note an association between antibiotic exposure and respiratory viral infections (RVIs). Antibiotics affect microbiota and impair immune response against RVIs in mice, and low microbiome diversity is associated with pulmonary complications including viral lower respiratory tract disease (LRTD) in hematopoietic cell transplantation (HCT) recipients. In this study, we examined whether antibiotic exposure was associated with increased risk of disease progression in RVIs post-transplantation...
May 16, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29772353/cardiac-profile-of-chimeric-antigen-receptor-car-t-cell-therapy-in-children-a-single-institution-experience
#5
Danielle Burstein, Shannon Maude, Stephen Grupp, Heather Griffis, Joseph Rossano, Kimberly Lin
BACKGROUND: Immunotherapy with chimeric antigen receptor (CAR)-modified T-cells targeting CD19 for pediatric acute lymphoblastic leukemia (ALL) has demonstrated significant efficacy. The principle toxicity is cytokine release syndrome with resultant hypotension. However, the spectrum of cardiovascular effects associated with CAR T-cell therapy has not been systematically evaluated. METHODS: We reviewed all patients who received CD19-directed CAR T-cells at the Children's Hospital of Philadelphia between April 2012 and September 2016...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29772352/allogeneic-stem-cell-transplantation-from-hla-mismatched-donors-for-pediatric-patients-with-acute-lymphoblastic-leukemia-treated-according-to-the-2003-bfm-and-2007-international-bfm-studies-impact-of-disease-risk-on-outcomes
#6
Jean-Hugues Dalle, Adriana Balduzzi, Peter Bader, Arjan Lankester, Isaac Yaniv, Jacek Wachowiak, Anna Pieczonka, Marc Bierings, Akif Yesilipek, Petr Sedlacek, Marianne Ifversen, Sabina Sufliarska, Jacek Toporski, Evgenia Glogova, Ulrike Poetschger, Christina Peters
RATIONAL: Allogeneic HSCT is beneficial for pediatric patients with relapsed or (very) high-risk ALL in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007-International study and were stratified according to relapse risk (Standard vs. High vs. Very High Risk of Relapse) and donor type (Matched Sibling vs. Matched Donor vs. Mismatched Donor). PATIENTS AND METHODS: A total of 148 patients (60% male, median age 8...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29772351/a-couple-based-communication-intervention-for-hematopoietic-cell-transplant-survivors-and-their-caregiving-partners-feasibility-acceptability-and-change-in-process-measures
#7
Shelby Langer, Laura Porter, Joan Romano, Michael Todd, Stephanie Lee
Hematopoietic cell transplantation (HCT) poses significant challenges for recipients and their caregiving partners. Couples may refrain from talking about treatment-related fears and concerns in order to minimize distress. This single-group, pre-post study examined feasibility and acceptability of an intervention designed to optimize communication between HCT patients and partners; it also assessed change in process measures. Couples met with a therapist five times to learn skills for disclosing illness-related thoughts and feelings and responding supportively to one another...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29772350/unmanipulated-haploidentical-hematopoietic-stem-cell-transplantation-achieved-outcomes-comparable-with-matched-unrelated-donor-transplantation-in-young-acquired-severe-aplastic-anemia
#8
Yue Lu, Rui-Juan Sun, Yan-Li Zhao, Min Xiong, Xing-Yu Cao, Jing-Pin Zhang, Zhi-Jie Wei, Jia-Rui Zhou, De-Yan Liu, Dao-Pei Lu
Salvage haploidentical HSCT is considered in patients with severe aplastic anemia (SAA) if matched unrelated donor (MUD) is unavailable. However, studies on haplo- and MUD transplantation in SAA are yet lacking. The present study retrospectively analyzed the outcomes of 89 young SAA patients who underwent unmanipulated alternative hematopoietic stem cell transplantation (HSCT) between September 2012 and September 2016 at our single center. 41 patients received haploidentical donors, and 48 patients received MUD for HSCT...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29758394/impact-of-thrombotic-microangiopathy-on-renal-outcomes-and-survival-after-hematopoietic-stem-cell-transplantation
#9
Merve Postalcioglu, Haesook T Kim, Faruk Obut, Osman Arif Yilmam, Jiqiao Yang, Benjamin C Byun, Sophie Kupiec-Weglinski, Robert Soiffer, Jerome Ritz, Joseph H Antin, Edwin Alyea, John Koreth, Corey Cutler, Philippe Armand, Julie M Paik, David E Leaf, Vincent T Ho, Reza Abdi
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT). We characterized the incidence, risk factors, and long-term outcomes associated with TA-TMA by performing a comprehensive review of all adult patients (n=1,990) undergoing allogeneic HSCT at the Dana Farber Cancer Institute/Brigham and Women's Hospital between 2005 and 2013. Using the City of Hope criteria, we identified 258 (13%) and 508 (26%) patients with "definite" and "probable" TMA, respectively...
May 11, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29758393/phase-i-trial-of-brentuximab-vedotin-for-steroid-refractory-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation
#10
Zachariah DeFilipp, Shuli Li, Maria E Kempner, Jami Brown, Candice Del Rio, Betsy Valles, Chrisa Hunnewell, Meredith Saylor, Julie Vanderklish, Bimalangshu R Dey, Areej El-Jawahri, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen
We conducted a phase I study of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). A modified 3+3 study design was used with the primary endpoint to determine the maximum tolerated dose (MTD) of BV in this population. Escalating doses of BV were planned, starting with 0.6 mg/kg q3weeks (dose level 0) and increasing by 0.3 mg/kg per dose level. BV was administered in 21-day cycles for up to 16 cycles of therapy...
May 11, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753839/platelet-transfusion-refractoriness-in-single-unit-cord-blood-transplantation-for-adults-risk-factors-and-clinical-outcomes
#11
Susumu Tanoue, Takaaki Konuma, Seiko Kato, Maki Oiwa-Monna, Masamichi Isobe, Koji Jimbo, Satoshi Takahashi, Arinobu Tojo
Platelet transfusion refractoriness (PTR) is frequently observed after allogeneic hematopoietic cell transplantation (HCT). However, the incidence of and risk factors for PTR, and impact of PTR on transplant outcomes after cord blood transplantation (CBT) have not been fully investigated. We retrospectively analyzed 185 adult patients who received single-unit CBT in our institute. The mean 16-hour corrected count increment (CCI) for the 5,840 platelet transfusions was 3.68×109 /l. Among them, 3,196 transfusions (54...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753838/wilms-tumor-1-wt1-expression-using-a-standardized-european-leukemia-net-certified-assay-compared-to-other-methods-for-detection-of-minimal-residual-disease-in-mds-and-aml-patients-after-allogeneic-blood-stem-cell-transplantation
#12
Christina Rautenberg, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, Kathrin Nachtkamp, Mustafa Kondakci, Stefanie Geyh, Dagmar Wieczorek, Rainer Haas, Ulrich Germing, Guido Kobbe, Thomas Schroeder
Overexpressed Wilms' Tumor 1 (WT1) gene is informative in many patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is measurable in peripheral blood (PB). Despite these advantages WT1 has not broadly been established as marker for minimal residual disease (MRD) monitoring after allogeneic transplantation (allo-HSCT) due to limited patient numbers, differing sample sources and non-standardized in-house methods. To estimate its value as MRD marker we serially quantified PB WT1 expression using a standardized European Leukemia Net-certified assay in 59 patients with AML and MDS after allo-HSCT...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753837/status-of-nk-cell-recovery-in-day-21-bone-marrow-after-allogeneic-hematopoietic-stem-cell-transplantation-predicts-clinical-outcome
#13
Norimichi Hattori, Bungo Saito, Yohei Sasaki, Shotaro Shimada, So Murai, Maasa Abe, Yuta Baba, Megumi Watanuki, Shun Fujiwara, Yukiko Kawaguchi, Nana Arai, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Hiroshi Harada, Tsuyoshi Nakamaki
Rapid immune recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important for clinical outcome prediction. In most studies, immune recovery after allo-HSCT has been monitored via peripheral blood. However, few reports regarding the status of absolute lymphocyte subsets in the bone marrow (BM) microenvironment have been undertaken. Therefore, we evaluated the clinical impact of immune recovery in the early period following allo-HSCT using BM samples. We showed that delayed natural killer (NK) cell recovery was independently associated with a poor prognosis for overall survival (hazard ratio (HR), 3...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753836/a-modified-intensive-strategy-to-prevent-cmv-disease-in-seropositive-umbilical-cord-blood-transplant-recipients
#14
Joshua A Hill, Steven A Pergam, Emily Cox, Hu Xie, Wendy M Leisenring, Michael Boeckh, Colleen Delaney, Filippo Milano
We previously demonstrated a lower rate of CMV reactivation and disease among seropositive umbilical cord blood transplant (CBT) recipients receiving an intensive prophylaxis strategy consisting of ganciclovir on days -8 to -2 pre-transplant, high-dose valacyclovir post-transplant, and twice-weekly serum CMV PCR testing. We hypothesized that a modified intensive strategy excluding pre-transplant ganciclovir would be similarly effective. We compared the risk of CMV reactivation, occurrence of CMV disease, and duration of anti-CMV therapy by day 100 post-CBT in patients receiving the modified intensive and intensive strategies...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753835/umbilical-cord-blood-expansion-are-we-there-yet
#15
Troy C Lund
No abstract text is available yet for this article.
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753163/baseline-renal-function-and-albumin-are-powerful-predictors-for-allogeneic-transplantation-related-mortality
#16
Roni Shouval, Cornelis N de Jong, Joshua Fein, Annoek E C Broers, Ivetta Danylesko, Avichai Shimoni, Marloes R Reurs, Adája E Baars, Niels van der Schaft, Arnon Nagler, Jan J Cornelissen
RATIONALE: Biomarkers measured in blood chemistry before allogeneic hematopoietic stem cell transplantation (HSCT) may reflect patients' physiological status. We hypothesized that selected markers are predictive for non-relapse mortality (NRM) following transplantation and could contribute to risk assessment. PATIENTS AND METHODS: We investigated the value of pre-HSCT albumin, estimated glomerular filtration rate (eGFR) and alkaline phosphatase (AlkP) in predicting NRM...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753162/steroid-s-deleterious-effect-on-cmv-infection-rate-post-allo-sct-depends-on-pre-transplant-cmv-serostatus-of-donors-and-recipients
#17
María Suárez-Lledó, Núria Martínez-Cibrián, Gonzalo Gutiérrez-García, Veselka Dimova-Svetoslavova, Ma Angeles Marcos, Beatriz Martín-Antonio, Alejandra Martínez-Trillos, Neus Villamor, Laura Rosiñol, Carmen Martínez, Francesc Fernández-Avilés, Carolina García-Vidal, Álvaro Urbano-Ispizua, Montserrat Rovira
This study examined the impact of prednisone (PDN) on CMV infection after allogeneic stem cell transplantation (allo-SCT) according to donor (D) and recipient (R) CMV serostatus. Seventy-five patients underwent allo-SCT from June 2010 to July 2012. The risk of CMV infection according to D and R serostatus was defined as follows: high risk (HR) (D-/R+), intermediate risk (IR) (D+/R+ and D+/R-) and low risk (LR) (D-/R-). Forty-five patients (60%) developed CMV infection and forty-six patients (61%) received steroids (PDN ≥ 1 mg/kg/day) to treat acute Graft versus host disease (GvHD)...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753161/engagement-with-inspire-an-online-program-for-hematopoietic-cell-transplantation-survivors
#18
Karen L Syrjala, Marie-Laure Crouch, Wendy M Leisenring, Mary E D Flowers, Samantha B Artherholt, Allison Stover Fiscalini, Eleni Romano, Joan M Romano, Paul J Martin, Jean C Yi
PURPOSE: In a secondary analysis of a randomized controlled trial (RCT), we examined engagement with INSPIRE, a personalized online program for hematopoietic cell transplantation (HCT) survivors that focused on cancer-related distress, depression, fatigue, and health care needs. METHODS: We approached all adult, 3-18 year HCT survivors treated for hematologic malignancy, without relapse or second cancer in the previous 2 years, for participation in an RCT with either immediate or delayed access to INSPIRE...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753160/get-outta-here-addition-of-mobilizing-agents-to-conditioning-regimen-improves-donor-engraftment-after-allogeneic-hematopoietic-stem-cell-transplantation-for-wiskott-aldrich-syndrome
#19
Michael P Rettig
No abstract text is available yet for this article.
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753159/defining-incidence-and-risk-factors-for-catheter-associated-bloodstream-infections-in-an-outpatient-adult-hematopoietic-cell-transplant-program
#20
Marissa K McDonald, Kathryn A Culos, Katie S Gatwood, Caleb Prow, Heidi Chen, Bipin N Savani, Michael Byrne, Adetola A Kassim, Brian G Engelhardt, Madan Jagasia, Gowri Satyanarayana
BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) patients are at an increased risk of developing central line-associated bloodstream infections (CLABSIs) due to prolonged periods of myelosuppression, immunosuppression, and indwelling catheter days. CLABSIs are among the most serious complications in HCT recipients and can lead to prolonged hospitalizations, intensive care unit (ICU) admissions, lengthy antimicrobial therapies, and increased mortality. There is a lack of data regarding the incidence and risk factors associated with the development of CLABSIs in the HCT population undergoing outpatient transplantation...
May 9, 2018: Biology of Blood and Marrow Transplantation
journal
journal
20050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"